See more : IDM S.A. (IDM.WA) Income Statement Analysis – Financial Results
Complete financial analysis of DocMorris AG (ZRSEF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DocMorris AG, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Mountain Pacific Bancorp, Inc. (MPCB) Income Statement Analysis – Financial Results
- CB Industrial Product Holding Berhad (CIHPF) Income Statement Analysis – Financial Results
- Manolete Partners Plc (MANOF) Income Statement Analysis – Financial Results
- Zeder Investments Ltd. (ZED.JO) Income Statement Analysis – Financial Results
- TFBS Bioscience Inc. (6939.TWO) Income Statement Analysis – Financial Results
DocMorris AG (ZRSEF)
About DocMorris AG
DocMorris AG operates e-commerce pharmacies and a wholesale business for medical and pharmaceutical products in Switzerland and internationally. The company offers consumer health, beauty, and personal care products, as well as medicines management services. It also operates stationary pharmacy shops. The company sells its products directly to physicians, online mail-order pharmacies, and private individuals under the Zur Rose, PromoFarma, TeleClinic, and DocMorris brands. The company was formerly known as Zur Rose AG and changed its name to Zur Rose Group AG in May 2015. The company was founded in 1993 and is headquartered in Frauenfeld, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 969.46M | 1.61B | 1.73B | 1.48B | 1.36B | 1.21B | 982.92M | 879.54M | 834.42M | 915.55M | 910.61M | 523.31M | 487.19M | 488.27M |
| Cost of Revenue | 766.11M | 1.36B | 1.47B | 1.24B | 1.15B | 1.02B | 836.34M | 747.61M | 708.73M | 775.87M | 772.10M | 448.09M | 415.72M | 416.05M |
| Gross Profit | 203.35M | 245.63M | 260.05M | 241.33M | 208.65M | 191.21M | 146.58M | 131.93M | 125.69M | 139.68M | 138.51M | 75.21M | 71.47M | 72.22M |
| Gross Profit Ratio | 20.98% | 15.27% | 15.06% | 16.34% | 15.39% | 15.84% | 14.91% | 15.00% | 15.06% | 15.26% | 15.21% | 14.37% | 14.67% | 14.79% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 25.53M | 59.18M | 52.89M | 50.88M | 34.89M | 24.91M | 27.44M | 21.50M | 18.88M | 21.44M | 24.27M | 14.90M | 11.90M | 11.90M |
| Selling & Marketing | 96.57M | 106.21M | 173.39M | 109.74M | 53.21M | 74.40M | 60.22M | 44.87M | 36.29M | 41.83M | 48.06M | 24.29M | 23.47M | 22.14M |
| SG&A | 122.10M | 165.39M | 226.28M | 160.62M | 88.10M | 99.31M | 87.65M | 66.37M | 55.16M | 63.26M | 72.33M | 39.19M | 35.37M | 34.03M |
| Other Expenses | 81.25M | 663.00K | 626.00K | 519.00K | 437.00K | 452.00K | 441.00K | 435.00K | 447.00K | 469.00K | 458.00K | 424.00K | 583.00K | 602.00K |
| Operating Expenses | 203.35M | 404.58M | 457.27M | 359.49M | 273.19M | 223.06M | 173.61M | 139.45M | 117.70M | 131.95M | 144.71M | 72.99M | 67.32M | 65.22M |
| Cost & Expenses | 969.46M | 1.77B | 1.92B | 1.60B | 1.42B | 1.24B | 1.01B | 887.06M | 826.43M | 907.82M | 916.81M | 521.08M | 483.04M | 481.27M |
| Interest Income | 2.22M | 592.00K | 533.00K | 1.16M | 54.00K | 239.00K | 12.00K | 36.00K | 165.00K | 63.00K | 122.00K | 144.00K | 162.00K | 145.00K |
| Interest Expense | 19.14M | 17.73M | 16.19M | 14.73M | 5.28M | 1.70M | 2.30M | 2.48M | 2.47M | 2.37M | 2.47M | 1.08M | 1.15M | 1.25M |
| Depreciation & Amortization | 43.44M | 39.64M | 49.86M | 38.04M | 30.57M | 18.55M | 11.51M | 8.65M | 7.36M | 9.13M | 7.79M | 4.76M | 4.75M | 6.57M |
| EBITDA | -56.08M | -111.94M | -159.36M | -79.23M | -31.35M | -17.99M | -17.09M | -1.02M | 13.87M | 16.02M | -4.02M | 12.02M | 9.94M | 12.89M |
| EBITDA Ratio | -5.78% | -6.60% | -9.23% | -5.36% | -2.31% | -1.36% | -1.05% | 0.08% | 1.51% | 1.75% | 0.17% | -0.75% | 2.04% | 2.68% |
| Operating Income | -82.57M | -168.82M | -210.48M | -117.63M | -45.71M | -31.40M | -21.19M | -7.09M | 8.44M | 8.21M | -11.26M | 7.52M | 5.19M | 7.43M |
| Operating Income Ratio | -8.52% | -10.50% | -12.19% | -7.96% | -3.37% | -2.60% | -2.16% | -0.81% | 1.01% | 0.90% | -1.24% | 1.44% | 1.06% | 1.52% |
| Total Other Income/Expenses | -36.09M | -18.26M | -333.50M | -15.58M | -137.30M | -5.68M | -15.31M | -5.63M | -4.40M | -3.69M | -3.01M | -952.00K | -931.00K | -2.36M |
| Income Before Tax | -118.66M | -169.87M | -226.68M | -133.21M | -50.11M | -38.55M | -36.51M | -12.72M | 4.04M | 4.52M | -14.28M | 6.57M | 4.07M | 5.07M |
| Income Before Tax Ratio | -12.24% | -10.56% | -13.13% | -9.02% | -3.70% | -3.19% | -3.71% | -1.45% | 0.48% | 0.49% | -1.57% | 1.26% | 0.84% | 1.04% |
| Income Tax Expense | -1.09M | 1.25M | -949.00K | 2.44M | 2.27M | 553.00K | -241.00K | 53.00K | 598.00K | -2.64M | 1.19M | 415.00K | -4.60M | 1.15M |
| Net Income | 82.28M | -171.12M | -225.74M | -135.70M | -52.36M | -38.97M | -36.24M | -12.77M | 3.45M | 7.15M | -15.46M | 6.14M | 8.67M | 3.92M |
| Net Income Ratio | 8.49% | -10.64% | -13.07% | -9.19% | -3.86% | -3.23% | -3.69% | -1.45% | 0.41% | 0.78% | -1.70% | 1.17% | 1.78% | 0.80% |
| EPS | 10.07 | -15.88 | -23.40 | -14.95 | -6.04 | -6.14 | -6.94 | -2.82 | 1.01 | 2.11 | -4.57 | 1.92 | 2.72 | 0.86 |
| EPS Diluted | 7.05 | -15.88 | -23.40 | -14.95 | -6.04 | -6.14 | -6.94 | -2.82 | 1.01 | 2.11 | -4.57 | 1.92 | 2.72 | 0.86 |
| Weighted Avg Shares Out | 8.17M | 10.78M | 9.65M | 9.08M | 8.66M | 6.35M | 5.22M | 4.54M | 3.39M | 3.38M | 3.39M | 3.19M | 3.19M | 4.53M |
| Weighted Avg Shares Out (Dil) | 11.67M | 10.78M | 9.65M | 9.08M | 8.66M | 6.35M | 5.22M | 4.54M | 3.39M | 3.38M | 3.39M | 3.19M | 3.19M | 4.53M |
DocMorris AG (ZRSEF) Q2 2024 Earnings Call Transcript
DocMorris AG (ZRSEF) Q4 2023 Earnings Call Transcript
Online drug retailer DocMorris meets expectations as cost savings help
Online drug retailer DocMorris trims top end of 2023 outlook
Source: https://incomestatements.info
Category: Stock Reports